Quick Answer
NeuroSense Therapeutics Ltd. reported Stockholders Equity of -$1.56 million for fiscal year 2025.
NeuroSense Therapeutics Ltd. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$1.56M | -160.4% |
| 2024 | $2.58M | +246.8% |
| 2023 | -$1.76M | -130.1% |
| 2022 | $5.84M | -46.1% |
| 2021 | $10.83M | — |
- NeuroSense Therapeutics Ltd. showed a decrease of -160.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, NeuroSense Therapeutics Ltd.’s stockholders equity has declined by 114.4% (from $10.83 million to -$1.56 million).
- The most recent figure is from NeuroSense Therapeutics Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: